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Abstract
Improved methods for targeting HIV testing among patients most likely to be infected are required; HIDES I aimed to define
the methodology of a European wide study of HIV prevalence in individuals presenting with one of eight indicator
conditions/diseases (ID); sexually transmitted infection, lymphoma, cervical or anal cancer/dysplasia, herpes zoster, hepatitis
B/C, mononucleosis-like illness, unexplained leukocytopenia/thrombocytopenia and seborrheic dermatitis/exanthema, and
to identify those with an HIV prevalence of .0.1%, a level determined to be cost effective. A staff questionnaire was
performed. From October 2009– February 2011, individuals, not known to be HIV positive, presenting with one of the ID
were offered an HIV test; additional information was collected on previous HIV testing behaviour and recent medical history.
A total of 3588 individuals from 16 centres were included. Sixty-six tested positive for HIV, giving an HIV prevalence of 1.8%
[95% CI: 1.42–2.34]; all eight ID exceeded 0.1% prevalence. Of those testing HIV positive, 83% were male, 58% identified as
MSM and 9% were injecting drug users. Twenty percent reported previously having potentially HIV-related symptoms and
52% had previously tested HIV negative (median time since last test: 1.58 years); which together with the median CD4 count
at diagnosis (400 cell/uL) adds weight to this strategy being effective in diagnosing HIV at an earlier stage. A positive test
was more likely for non-white individuals, MSM, injecting drug users and those testing in non-Northern regions. HIDES I
describes an effective strategy to detect undiagnosed HIV infection. All eight ID fulfilled the .0.1% criterion for cost
effectiveness. All individuals presenting to any health care setting with one of these ID should be strongly recommended an
HIV test. A strategy is being developed in collaboration with ECDC and WHO Europe to guide the implementation of this
novel public health initiative across Europe.
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Background
Of the estimated 2.3 million HIV infected individuals living in
the European Region, it is estimated that one in three are unaware
of their diagnosis [1–3]. Among those diagnosed with HIV, 50%
have a CD4 count ,350 cells/uL at diagnosis, negatively
impacting on both individual and public health [4,5]. Late
diagnosis is associated with increased morbidity and mortality [6–
9], poorer response to antiretroviral treatment [10–12], increased
rates of HIV transmission [13] and increased healthcare costs
[14,15]. A critical public health issue is, therefore, how to diagnose
individuals with HIV infection at an earlier stage of disease. This
will require the introduction of innovative approaches to better
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target testing for those most likely to be infected with HIV and
who present late for care.
Certain ‘‘indicator’’ conditions occur more frequently in HIV-
infected individuals, either because they share a common mode of
transmission or because their occurrence is facilitated by the
characteristic immune deficiency associated with HIV infection.
There is little evidence, however, regarding the prevalence of HIV
infection in individuals of unknown HIV status presenting for care
with such conditions [16]. Data from the US and France
[17,18,19] suggest that delivering testing in settings with an HIV
prevalence of at least 0.1% is cost effective. Some testing guidelines
now promote indicator condition guided HIV testing as part of an
overall provider initiated testing strategy [20,21]. However, little
evidence exists to support such a strategy. In response to the
sustained high levels of undiagnosed HIV across Europe,
consensus was reached at the HIV in Europe 2007 Conference
[16], to propose an indicator condition guided testing approach.
The HIDES study (HIV Indicator Diseases across Europe Study)
was subsequently designed by the HIV in Europe initiative (www.
hiveurope.eu).
The overall objective of HIDES was to identify those indicator
diseases/conditions (ID) with an HIV prevalence of .0.1% and to
ascertain whether there is variation in prevalence across Europe.
HIDES I aimed to define the methodology of such an approach, to
determine the HIV prevalence of eight pre-selected ID, and to
describe the characteristics of those testing HIV positive, their
previous HIV testing behaviour and whether missed opportunities
for earlier diagnosis could be identified.
Methods
Eight indicator conditions were selected for inclusion based on a
combination of factors including: a significant health risk if HIV
remained undiagnosed, the opportunity of identifying early
infection/seroconversion, the likelihood of a high HIV prevalence
in the ID, or expert opinion underpinned by clinical experience
and best available evidence [16,20,21]. TB and other AIDS
defining illnesses were not included as there is already wide spread
acceptance of the need for HIV testing in these conditions. Given
the paucity of data regarding HIV prevalence for other conditions,
the focus of this study was on other IDs to provide the evidence of
HIV prevalence .0.1%.
Recruitment was by a call for expression of interest to more
than 200 healthcare centres across Europe; healthcare settings
were eligible for consideration if they handled one or more of the
following eight conditions as part of their routine delivery of care:
N Sexually transmitted infections (STI)
N Malignant lymphoma, irrespective of type (LYM)
N Cervical or anal cancer/dysplasia (CAN)
N Herpes zoster (HZV)
N Hepatitis B or C virus infection, acute or chronic, and
irrespective of time of diagnosis relative to survey (HEP)
N Ongoing mononucleosis-like illness (MON)
N Unexplained leukocytopenia/thrombocytopenia lasting .4
weeks (CYT)
N Seborrheic dermatitis/exanthema (SEB)
Thirty-five centres responded to the call for collaboration.
Seventeen centres were excluded due to very low expected
recruitment numbers and two were subsequently unable to start
prospective recruitment due to administrative obstacles. Centres
were selected based on the estimated number of presenting cases of
the relevant ID and the predicted recruitment time; selection was
also based on the aim to deliver a balanced number of surveys per
ID within the study overall. Therefore each centre was invited to
recruit only to a proportion of the eight IDs. One survey was
defined as prospectively delivered routine HIV testing for a single
ID at each individual centre. Ethical approval was obtained in all
participating countries in line with their National standards. In the
majority of settings, where relevant, training for delivering HIV
testing was delivered to local staff, and resources made available
for support and referral. In two settings specific training was not
delivered, but support was provided or the STI/HIV clinic staff
did the testing.
Consecutive patients were enrolled from October 2009–
February 2011 if they presented with the selected ID and were
not already known to be HIV positive. Patient inclusion was based
on the treating physician’s clinical, microbiological or histological
diagnosis. All patients were offered an HIV test and the outcome
of the test was recorded. Centres could use either rapid point of
care or serological HIV tests. Additional information, including
demographics, previous HIV testing behaviour and relevant past
medical history (previous AIDS-related symptoms), hospital
admissions, and prior or past STI and viral hepatitis testing
behaviour was collected by the treating health care provider. Data
were transmitted to the central co-ordinating centre for entry and
analysis.
In addition, a questionnaire was completed by survey coordi-
nators and clinical staff delivering the testing, at its conclusion.
This examined the attitudes of health care workers towards routine
HIV testing for the specific ID and explored the challenges
encountered. Unpublished prevalence data was collected from
participating study sites for comparison with the prevalence found
in the IDs.
For the purposes of this analysis patients were divided into four
geographic regions as previously defined by EuroSIDA [22]:
North (Denmark, Sweden, Netherlands, UK), West Central
(Austria, Belgium, Germany), East Central (Belarus, Bosnia,
Croatia, Poland, Ukraine) and South (Italy and Spain).
Patient characteristics were compared using the Chi-squared
test for categorical, and the Kruskall-Wallis test for continuous,
variables. The exact binomial method was used to calculate the
95% confidence intervals for HIV prevalence for each ID. Logistic
regression was used to investigate which factors were associated
with a HIV-positive diagnosis in this study. Each factor was fitted
individually into a univariable model. Multivariable models were
developed using variables found to be significant (p,0.10) in
univariable analyses. A stepwise selection method was used to
confirm final model selection. All analyses were performed using
SAS version 9.2 [23].
Results
Centre Characteristics
Thirty-nine surveys were thus conducted at 16 sites in 14
countries. All centres were urban, hospital based services, except
for Barcelona, where recruitment took place at four primary care
units collaborating with the hospital, and Brussels, where
recruitment was in both hospital and primary care.
Twelve surveys were carried out in outpatient departments,
three in inpatient settings, eight in a combination of outpatient and
inpatient, four in primary care and two in a combination of
outpatient clinic and primary care. Before the HIDES study was
introduced, testing for HIV was considered routine in less than
half the settings (11/29). Local clinic staff performed the HIV test
in 23 of the surveys, in one survey STI/HIV clinic staff did the
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testing, and in eight surveys it was a combination of local clinical
staff and STI/HIV staff.
Patient Characteristics
A total of 3588 individuals accepted the offer of an HIV test.
Patient characteristics are detailed in Table 1, according to the
region of enrolment. The highest proportion of individuals was
recruited in East Central Europe (n = 1412, 39%), followed by
North Europe (n = 1288, 36%). In North Europe, the median age
was lower compared to the other regions, and a higher proportion
of females were recruited. In East Central almost all the
individuals enrolled reported their sexual orientation as hetero-
sexual (97%) compared to approximately 60% in other regions. A
lower proportion of individuals in East Central Europe (13%)
reported having had a previous HIV test.
HIV Prevalence by Indicator Condition
Of the 3588 individuals included, sixty-six were diagnosed with
HIV, yielding an overall prevalence of 1.8% [95% CI: 1.42–2.34].
Table 2 indicates the prevalence of HIV by ID. All eight ID
individually fulfilled the study’s criteria of demonstrating an HIV
prevalence of.0.1%, however, for LYM and CAN, 0.1 fell within
the 95% confidence interval. The highest prevalence was found in
STI: 4.06% [95% CI 2.78–5.71].
Table 3 shows the HIV prevalence according to ethnicity
(stratified as white vs. non-white) and by region of recruitment.
The prevalence of HIV was highest in Southern Europe, where an
HIV prevalence of .5% was observed in both whites and non-
whites, and lowest in North Europe (,1%). Of the 2348
individuals who identified as heterosexual, white and non-IDU
(Intravenous Drug User) (i.e. demographically ‘lower risk’), 19
tested positive, giving an HIV prevalence of 0.81% (95% CI 0.48–
1.26).
Characteristics of Individuals who Tested Positive for HIV,
and Potential Missed Opportunities for Earlier Diagnosis
Of patients testing HIV positive 83.3% were male, 85.0% were
white, 57.6% identified themselves as homo- or bi-sexual and
9.1% as injecting drug users. More than half (51.5%) had
previously tested HIV negative; the median time since the last
HIV test was 1.6 years (range 0.05–12.71 years). In the preceding
five years, 27 (54.0%) individuals had made at least one visit to a
sexual health clinic, 13 (19.7%) had experienced potential HIV-
related symptoms, and 7 (10.0%) individuals had been admitted to
hospital, the majority with a potential AIDS diagnosis or infection.
The presenting CD4 T-cell count was available for 35 (53%)
individuals who tested HIV-positive, with a median of 400 cells/
mL (range 11–675).
Predictors of Testing HIV Positive
In unadjusted analysis, individuals presenting with LYM (OR
0.07, 95%CI 0.009–0.51, p = 0.008), CAN (OR, 0.09, 95%CI
0.02–0.37, p = 0.0009), and HEP (0.09, 95%CI 0.03–0.25),
p,.0001) were less likely to test HIV positive than those
presenting with STI. There was no significant difference in the
odds of testing HIV positive in those presenting with HZV
Table 1. Patient characteristics by European region.
European Region1
North West Central East Central South p-value
Total (N,%) 1288 (35.9) 459 (12.8) 1412 (39.4) 429 (12.0)
Gender (N,%) Male 567 (44.0) 302 (65.8) 817 (57.9) 292 (68.1) ,.0001
Female 716 (55.6) 157 (34.2) 591 (41.9) 136 (31.7)
Ethnicity White 999 (77.6) 288 (84.7) 1390 (99.0) 385 (89.7) ,.0001
Age (median IQR2) 33 (28–46) 37 (28–47) 37 (26–51) 43 (32–59) ,.0001
Sexual orientation (N,%) Heterosexual 717 (55.7) 274 (59.7) 1365 (96.7) 263 (61.3) ,.0001
Homosexual/bisexual 146 (11.3) 32 (7.0) 19 (1.3) 93 (21.7)
Unknown 425 (33.0) 153 (33.3) 28 (1.9) 73 (17.0)
Previous HIV test (N,%) 743 (57.7) 209 (45.5) 185 (13.1) 153 (35.6) ,.0001
Indicator condition3
(N,%)
STI 526 (40.8) 103 (22.4) 0 (0.0) 135 (31.5) ,.0001
LYM 88 (6.8) 6 (1.3) 250 (17.7) 0 (0.0)
CAN 374 (29.0) 122 (26.6) 46 (3.3) 0 (0.0)
HZV 0 (0.0) 102 (22.2) 84 (6.0) 21 (4.9)
HEP 291 (22.6) 68 (14.8) 606 (42.9) 134 (31.2)
MON 0 (0.0) 2 (0.4) 414 (29.3) 25 (5.8)
CYT 4 (0.3) 0 (0.0) 12 (0.9) 78 (18.2)
SEB 5 (0.4) 56 (12.2) 0 (0.0) 36 (8.4)
Number tested HIV
positive (N,%)
8 (0.6) 7 (1.5) 23 (1.6) 28 (6.5) ,.0001
1North:Denmark, Sweden, Netherlands, UK, West Central: Austria, Belgium, Germany, East Central: Belarus, Bosnia, Croatia, Poland, Ukraine and South: Italy and Spain.
2IQR:Interquartile range.
3STI: Sexually transmitted infection, LYM: Malignant lymphoma, CAN: Cervical or anal cancer/dysplasia, HZV: Herpes zoster, HEP: Hepatitis B or C, MON: Ongoing
mononucleosis-like illness, CYT: Unexplained leukocytopenia/thrombocytopenia lasting .4 weeks, SEB: Seborrheic dermatitis/exanthema (SEB).
Missing data: 10 (0.3%) gender, 120 (3.3%) ethnicity, 63 (1.8%) age, 120 (3.3%) sexual orientation, 291 (8.1%) previous HIV test.
doi:10.1371/journal.pone.0052845.t001
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(p = 0.44), MON (p = 0.86), CYT (p = 0.69) or SEB (p = 0.34) and
those with STI. After adjustment for ethnicity, sexual orientation,
active IDU status, whether or not the individual had previously
had tested for hepatitis B, and region of Europe, there were no
significant differences between presenting ID in odds of testing
HIV positive.
Factors that were independently associated with testing HIV
positive are shown in Figure 1. Individuals who were of non-white
ethnic origin (adjusted odds ratio [OR] 4.73, 95%CI 2.16–
12.61,p = 0.0002), homosexual/bisexual (aOR 23.72, 95%CI
10.20–55.17, p,.0001) or active IDU (aOR 10.86, 95%CI
3.52–33.50, p,0.0001) were more likely to test HIV positive.
Additionally, individuals enrolled from West Central (aOR 3.76,
95% CI 1.01–14.04, p = 0.04), East Central (aOR 9.12 95%CI
2.04–40.79, p = 0.003) or South (aOR 6.25, 95% CI 1.81–21.52,
p = 0.003) were more likely to test HIV positive compared to
individuals from North Europe.
Acceptability of HIV Test Offer
For those surveys where the proportion of eligible patients
offered an HIV test is available (7 centres, 16 surveys) median
coverage in hospital settings was 92% (range 66–100%), and 12%
in primary care (Chi square p-value,0.0001). The median uptake
in both settings was 96% (range 62–100%). Due to difficulty with
data collection/disease reporting at some centres, this data is not
available for all surveys.
Questionnaire Study
Thirty of 39 questionnaires were received from survey
coordinators (77% return rate). Fifty-three percent reported they
perceived that motivation of colleagues was a barrier to the
implementation of the surveys. When asked about colleagues’
attitudes towards the study, 10% said they thought their colleagues
were positive, 43% considered they were neutral and 36% felt they
were sceptical.
Sixty-two short questionnaires were received from the clinical
staff delivering the testing. Time pressure was reported by 47% as
a barrier to offering an HIV test as part of routine care, 13% had
concerns they would be asked difficult questions, 10% felt deskilled
and 7% expressed a need for additional training. Reasons for not
offering a test routinely were reported to be due to lack of time or
because the patient was not perceived to be at risk (both at 32%),
because they forgot (25%), or because the patient reported a recent
test (16%).
Discussion
For the first time, HIDES I has demonstrated an effective
indicator condition guided HIV testing strategy in Europe,
effectively diagnosing individuals with HIV infection. Phase I of
the study has demonstrated proof of concept, showing that such an
approach is both feasible and acceptable.
All eight IDs individually fulfilled the criteria of demonstrating
an HIV prevalence of .0.1%, with some variation. Despite the
Table 2. Prevalence of HIV by indicator condition.
Individuals
having HIV
test
(number)
HIV positive
(number)
Prevalence
(95% CI )
Number of
surveys
Local HIV
prevalence*
Country HIV
prevalence***
Total 3588 66 1.84 (1.42–2.34) 39 0.1–1.1
Indicator condition
Sexually transmitted infection (STI) 764 31 4.06 (2.78–5.71) 4 0.8–3.0 0.2–0.3
Malignant lymphoma (LYM) 344 1 0.29 (0.006–1.61) 5 0.8 0.1–0.2
Cervical or anal dysplasia or cancer (CAN) 542 2 0.37 (0.04–1.32) 4 0.8 0.1–0.2
Herpes zoster (HZV) 207 6 2.89 (1.07–6.21) 5 0.3–0.9 0.1–0.4
Hepatitis B or C (HEP) 1099 4 0.36 (0.10–0.93) 6 0.2–2.8** 0.1–1.1
Ongoing mononucleosis-like illness (MON) 441 17 3.85 (2.26–6.10) 7 0.2–0.9 0.3–1.1
Unexplained leukocytopenia/thrombocytopenia
(CYT)
94 3 3.19 (0.66–9.04) 4 0.3–0.8 0.1–0.4
Seborrheic dermatitis/exanthema (SEB) 97 2 2.06 (0.25–7.24) 4 0.3–0.8 0.2–0.4
*Unpublished prevalence data from participating study sites.
**includes MSM, IDU prevalence.
***UNAIDS adults aged 15–49 country HIV prevalence rate [31].
doi:10.1371/journal.pone.0052845.t002
Table 3. Prevalence of HIV-positive test by ethnicity and region.
North West Central East Central South
Total number of tests (%) 1288 (35.9) 459 (12.8) 1412 (39.4) 429 (12.0)
Number tested HIV positive 8 (0.6) 17 (1.5) 23 (1.6) 28 (6.5)
White 0.60 (0.22–1.30) 1.04 (0.21–3.01) 1.65 (1.06–2.47) 6.23 (4.03–9.14)
non-white 0.69 (0.08–2.47) 2.34 (0.64–5.88) 0 (0–15.4) 9.09 (2.53–21.7)
doi:10.1371/journal.pone.0052845.t003
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recognition that these IDs are related to HIV infection and occur
more commonly in those infected, there are little data on
previously undiagnosed HIV prevalence among individuals
presenting with these conditions. Implementing this strategy across
Europe would have significant resource implications. However,
data from the US and France propose testing to be cost effective if
it is delivered at an HIV positivity rate of 0.1% [17,18,19], and the
results of HIDES I indicate this cut off is likely to be achieved for
each of the eight clinical conditions investigated. However, there
may be a degree of variation across Europe in regard to health
care utilization and costs, and further country specific data are
required to analyse cost effectiveness. Furthermore, in two of the
conditions, the target fell within the 95% CI. Increased
recruitment through the planned second phase (HIDES II) should
be able to further address these issues.
The high HIV prevalence in individuals presenting with a STI
is expected, as they share their route of transmission, and the
prevalence approaches those rates reported elsewhere (8.8–15.1%
among MSM attending UK GUM clinics, for example) [24].
However the high detection rate in STI in HIDES I, is also likely
to be influenced by the fact that clinics participating in the STI
surveys routinely offer HIV tests to all attending individuals
regardless of presenting complaint. This is likely to increase both
the offer rate and the uptake of testing, as patients expect to be
offered a test in this setting, and tests are offered by specialist
clinicians in a routine manner.
The HIV prevalence in individuals presenting with a mononu-
cleosis-like illness was also high at 3.85%, and it is possible these
symptoms represented HIV sero-conversion. Diagnosis at sero-
conversion has the added advantage of enabling an individual to
be aware of their HIV status at their most infectious stage, and
thus timely diagnosis may potentially impact on levels of onward
transmission [25].
Furthermore, a significant number of patients diagnosed with
HIV in the study overall had previously tested HIV negative, and
the short median time since their last negative test would suggest
early diagnosis had occurred in many of these individuals by
utilising this strategy. Additionally, the presenting median CD4
count for all patients diagnosed with HIV in the study is higher
than that reported at national levels [1,26] and adds further weight
to this strategy being effective in diagnosing HIV infection at an
earlier stage.
The differences in the patient characteristics observed are likely
to be due, in part, to different surveys being carried out in different
regions: 40% of individuals in Northern Europe were included in a
STI survey compared to none in East Central Europe; the
majority (43%) of individuals recruited in East Central Europe
were included in a hepatitis survey. Of individuals in East Central
Europe, 29% were included in a MON survey, significantly higher
compared to the other regions. This is due to the methodology,
whereby each centre only recruited to a proportion of the eight ID
(range 1–5), and the IDs were self-selected.
Although the odd ratio of testing HIV positive was higher in
those with well-recognised risk-factors (MSM, non-white ethnicity
and IDU) individuals presenting with an ID but not from these
groups had an HIV prevalence of 0.81%, still far exceeding the
0.1% target. Given that risk-based targeted testing as a strategy to
date has not been sufficiently effective, and that in many health
care settings information about risk factors is not sought or elicited,
indicator condition guided HIV testing is a worthy additional
strategy to enhance current testing programmes.
The uptake rates reported suggest the strategy is acceptable to
patients regardless of setting or ID, and is higher than that
reported elsewhere [27,28]. The offer rate, where available, varies
significantly between acute and primary care settings. The offer
rate in acute settings is higher than that reported elsewhere
Figure 1. Odd ratio for testing HIV positive.
doi:10.1371/journal.pone.0052845.g001
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[27,28]; in primary care it is lower than some reports [27,28],
however it is similar to some experience outside research studies
[unpublished data]. It may be the offer rate is a surrogate marker
of the strategy’s acceptability to staff, or it may represent
organisational factors within primary care impacting on feasibility.
This discrepancy warrants further study.
Staff involved in the study identified major barriers to delivering
ID guided testing, including operational, attitudinal barriers, and
training needs: however in the majority of settings this was not
reflected in light of the high offer and uptake rates. Some of this
may be due to study staff incorrectly attributing attitudes to local
clinic staff; however the clinic staff themselves did report a high
level of predominantly operational barriers, along with perceptions
of low risk. This is similar to that reported elsewhere [27,29] and
poses a significant challenge to rolling out any strategy calling for
increased testing and aiming to ‘normalise’ the offer of an HIV
test. It is possible that the introduction of indicator condition
guided testing could remove some of the health provider barriers
to the offer of a test. Removing the need for risk assessment and
making indicator conditions a trigger for the routine offer of an
HIV test has the potential to reduce HIV related stigma and
discrimination and increase the number of tests offered and
accepted, thus ‘normalising’ HIV testing.
Table 2 shows prevalence data (where available) for the
locations in which the surveys were conducted. In the majority
of cases (6/8) the prevalence identified through an ID driven
strategy exceeds the local prevalence, suggesting the strategy
would be an effective and efficient way of identifying HIV
infection, thereby helping to reduce the burden of undiagnosed
disease. In one ID, hepatitis, the prevalence range includes
prevalence figures for IDU and MSM populations - both high
prevalence populations themselves. In the remaining two ID,
lymphoma and CIN, the local prevalence data is only available for
one site, which contributed less than half the HIV tests, which
therefore makes comparison less reliable.
The comparator data are derived mainly from national
surveillance data. Other investigational testing strategies reveal
differing results, depending on whether they are targeted or
general screening HIV programmes in high prevalence areas.
These latter, general programmes largely produce lower preva-
lence figures than our ID driven testing. [29,30].
It is likely that the findings of this study overall are generalizable
across the European region, albeit requiring some local adapta-
tion. Acceptability, for example, is highly likely to be adversely
influenced by issues such as stigma, and access to treatment and
care. Prevalence in hepatitis will be affected by levels of IDU and
access to prevention programmes such as needle exchange. The
healthcare setting may also influence final prevalence rates with
different severity and/or chronicity of symptoms impacting on the
likelihood of underlying HIV infection. However data to date
would suggest, even allowing for such regional differences, the
resultant prevalence is likely still to remain above 0.1%. Close
monitoring and early review after introducing such a strategy
would inform the value of its continuation.
Clinics are encouraged to report audits on HIV prevalence for
the various IDs and to implement surveys for new ID conditions
through the HIDES II study and the HIV in Europe initiative
(www.hiveurope.eu).
Limitations
The relatively small number of patients enrolled in HIDES I has
resulted in wide CI around the prevalence estimates for some ID.
However the main aim of HIDES I was to define the methodology
and ascertain the acceptability and feasibility of the strategy of
indicator condition guided HIV testing; with further recruitment
to HIDES II more precise prevalence data should appear. There
was limited information for individuals testing HIV positive
regarding CD4 count at diagnosis, disease stage and access to care;
this will be an additional outcome in the second phase of the study.
Finally, there was very limited data available on those who
declined HIV testing or were not offered a test, which may have
introduced bias, as those who declined may have done so already
knowing their status. Additionally, staff may have introduced bias
by targeting testing on the basis of perceived risk, either high or
low.
Conclusions
Indicator condition guided HIV testing is an acceptable, feasible
and effective strategy to address the on-going HIV epidemic in
Europe by reducing the level of undiagnosed HIV infection, and
potentially facilitates earlier diagnosis. In line with ECDC
(European Centre for Disease Prevention and Control) guidance,
this study demonstrates that individuals presenting to any
healthcare setting with any of the eight indicator conditions
should be strongly recommended to have an HIV test.
The study has also reiterated that potential barriers to routine
testing still exist with clinicians, and this requires urgent address
through collaboration and information. A strategy is currently
being developed in collaboration with ECDC and WHO Europe
aimed at guiding the implementation of this novel public health
initiative across Europe. The follow up study, HIDES II, will
expand this testing strategy by increasing the number of indicator
conditions and centres involved.
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